Skip to main content
Clinical Trials/NCT01414400
NCT01414400
Completed
Not Applicable

Prospective Study of Bacteremia and Infection Rates Following Cholangioscopy With the Spyglass Cholangioscope

Stanford University1 site in 1 country72 target enrollmentAugust 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bile Duct Stricture
Sponsor
Stanford University
Enrollment
72
Locations
1
Primary Endpoint
Number of Patients With Bacteremia
Status
Completed
Last Updated
last year

Overview

Brief Summary

The aim of this study is to prospectively evaluate the frequency of bacteremia after ERCP/cholangioscopy using the Spyglass Direct Visualization System. In addition, the frequency of cholangitis/sepsis despite use of post procedural antibiotics will be studied.

Detailed Description

Rates of bacteremia (bacterial seeding of the blood) following ERCP's range from 6.4% to 18.0%. However, infectious complications of cholangitis/sepsis occur in only 0.5%- 3.0% of patients undergoing this procedure. The Spyglass Direct Visualization System allows cholangioscopy with direct visualization of the bile duct during ERCP by using a specialized small caliber endoscope. During the Spyglass portion of the procedure, saline is introduced into the bile duct to to irrigate the biliary system, in order to distend the biliary ducts and to improve visualization by clearing contrast, pus and stone debris. Saline irrigation may increase intrabiliary pressures and may therefore theoretically increase the risk for bacteremia and infection. The effect of Spyglass cholangioscopy and biliary irrigation on the frequency of bacteremia/post cholangioscopy infections is unknown and has not previously been studied. The aim of this study is to prospectively evaluate the frequency of bacteremia after ERCP/cholangioscopy using the Spyglass system.

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
December 2015
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Subhas Banerjee

Principle Investigator

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Biliary disease such as large stones necessitating electrohydraulic lithotripsy;
  • Biliary strictures needing tissue acquisition through cholangioscopic directed biopsies
  • Pancreatic-biliary malignancies needing tissue acquisition through cholangioscopic directed biopsies
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study.

Exclusion Criteria

  • Age \<18, \> 80
  • Potentially vulnerable subjects including pregnant women, homeless people, employees and students.
  • Patients who have a clear indication for pre-procedure antibiotics based on current ASGE guidelines
  • Patients who had received antibiotics for any reason within the prior 7 days
  • Patients who had evidence of systemic infection at time of the ERCP
  • Patients in whom additional venous access for blood cultures cannot be established.
  • Participation in another investigational study within the previous 90 days

Outcomes

Primary Outcomes

Number of Patients With Bacteremia

Time Frame: 1 week

This outcome is to assess bacteremia and infection rates in patients following Cholangioscopy with the Spyglass cholangioscope. Positive blood cultures were evaluated for transient ERCP-related bacteremia, and sustained Cholangioscopy-related bacteremia, defined by negative first and second sets of blood cultures but a positive third blood culture obtained 15 minutes after completion of Cholangioscopy and ERCP.

Study Sites (1)

Loading locations...

Similar Trials